Our demonstration that anti-IL-4Rα blockade effectively reduced TSLP secretion by asthma donor BECs acutely stimulated with the T2 cytokines suggests that reduction or normalization of TSLP levels may be an important mechanism, whereby anti-IL-4Rα therapy curbs T2-mediated inflammatory processes, preventing exacerbations in asthma patients. The gene discussed is TSLP; the disease is asthma.